Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
There is a clinical trial ongoing with bb2121, which is a CAR T-cell therapy against a B-cell maturation antigen (BCMA). This is an ongoing phase I dose-escalation study, states Jagannath. The results demonstrate the first 11 patients could be escalated further.
Overall, this has been well tolerated. Cytokine release syndrome was experienced but has only been shown to be of grade 1/2, states Jagannath.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
